ViroPharma AFFECTED by Clinical Hold and 4 Stock Analyses Trending Today

United Online, Inc. (NASDAQ:UNTD): Benchmark Co. believes that United Online, Inc. shares, at current levels, are not including any value for either of their Content & Media or Communications segments. The firm views the company’s decision to seek strategic alternatives for those units as a significant positive step towards unlocking their full value potential. Benchmark Co. keeps a Buy rating on their stock with a $6.50 price target.

Don’t Miss: Are These 5 TOP Stock Performers Overbought?

Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR): Canaccord said that Green Mountain Coffee Roasters Inc.’s guidance was reduced even though the quality improved and was not as bad as previously feared. The firm expects shares to recover and views valuation as “ridiculously cheap.” Shares are Buy rated with a $39 price target, down from $50.

Antigenics Inc. (NASDAQ:AGEN): Agenus Inc. reports a second quarter of 31c, and a consensus of 27c.

ViroPharma Inc. (NASDAQ:VPHM): Jefferies views the FDA’s clinical hold on Halozyme’s recombinant human hyaluronidase enzyme as a major setback. The firm lowered their price target for ViroPharma Inc., but keeps a Buy rating on their stock.

Bristol-Myers Squibb Company (NYSE:BMY): Brean Murray said Bristol-Myers Squibb Company’s (NYSE:BMY) suspension of their Hep-C study, due to safety issues, is a positive for Gilead (NASDAQ:GILD), given the safety profile of Sofosbuvir. In addition, the firm said the scarcity value surrounding Bristol’s failure has increased for Vertex’s (NASDAQ:VRTX) ALS-2200 and Identix’s (IDNX) IDX184, which are the only two nucleotides besides Sofosbuvir that are in active clinical development.

Don’t Miss: Did Electronic Arts Leave Facebook Hanging?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.